

The Board of Directors' of Medivir AB (publ) complete proposal for a resolution on a directed issue of shares

As announced on 7 February 2021, the Board of Directors proposes that the general meeting resolves to raise approximately SEK 27,828,000 by a directed issue of not more than 3,600,000 new class B shares.

The right to subscribe for the new class B shares in the directed issue shall, with deviation from the shareholders' pre-emption rights, be granted LINC AB. The reason for the deviation from the shareholders' preferential right is to strengthen the company's institutional shareholder base and the proceeds will be used to accelerate the company's existing business plan, mainly focusing on the development of MIV-818.

The shares shall have a subscription price per share of SEK 7.73, corresponding to the closing price of the company's share on 5 February 2021. For further information regarding the directed issue of shares see [Appendix A](#).

Huddinge, February 2021
Medivir AB (publ)
Board of Directors

Directed issue of shares to LINC AB

The Board of Directors proposes that the general meeting resolves to increase the company's share capital of not more than SEK 27,939,069.817022 by carrying out a directed issue of not more than 3,600,000 new class B shares (the "Share Issue") governed by the following terms and conditions. The maximum share capital increase is calculated based on the company's quota value as per the date of the announcement of the notice of the general meeting.¹

1. The right to subscribe for the new shares in the Share Issue shall, with deviation from the shareholders' pre-emption rights, fall upon LINC AB.
2. The subscription price per share shall be SEK 7.73, corresponding to the company's closing price on 5 February 2021.
3. The subscription price exceeds the previous shares' quota value. The exceeding amount shall be allocated to the free share premium reserve.
4. Subscription for the newly issued shares shall take place no later than on 15 March 2021. Subscription shall be made on a separate subscription list. However, the Board of Directors shall be entitled to extend the subscription period.
5. Payment for the subscribed shares shall be made no later than on 15 March 2021. However, the Board of Directors shall be entitled to extend the payment period.
6. The new shares in the company shall entitle to dividends from and including the first record day for dividend that is resolved following the registration of the Share Issue with the Swedish Companies Registration Office.

It is further proposed that the CEO should be authorized to undertake such minor adjustments in the decision that may be required for the registration with the Companies Registration Office and Euroclear Sweden AB.

The purpose of the Share Issue, and the reason for the deviation from the shareholders' preferential right, is to strengthen the company's institutional shareholder base and the proceeds will be used to accelerate the company's existing business plan, mainly focusing on the development of MIV-818.

A resolution in accordance with the Board of Directors' proposal is only valid if it has been approved by at least nine tenths (9/10) of the shares and votes represented at the meeting.

¹ Following registration of the general meeting's resolutions on the rights issue and the reductions of share capital which were announced on 13 January 2021, as well as the Board of Director's resolution to exercise the over-allotment option which was announced on 5 February 2021, the company's quota value is expected to amount to approximately SEK 3.881338.